Abstract: Substituted 1-benzylimidazole-5-methylidene hydantoins are disclosed as well as methods of preparing them, pharmaceutical compositions containing them, and methods of using them. Intermediates useful in the preparation of the compounds of the invention are also disclosed and synthetic methods for preparing the novel intermediates. The compounds are useful as antagonists of angiotensin II and thus are useful in the control of hypertension, hyperaldosteronism, congestive heart failure, surgically induced vascular smooth muscle proliferation, and glaucoma.

Abstract: A method for providing aqueous solutions of HOBr or HOCl which includes adding bleach (NaOCl) to a solution of HBr or HCl until an identified absorbance or color change in the resulting solution is detected. Dialkylhydantoins are optionally added to the resulting solution to suppress the formation of halate ions. The method provides a simple and reliable method for producing accurately defined solutions of hypohalous acids, which are useful in a variety of ways, including for disinfecting, cleaning, and odor control purposes.

Abstract: Compositions of dimethyloldimethylhydantoin, monomethyloldimethylhydantoin, and dimethylhydantoin having less than 0.1% by weight of free formaldehyde based upon 100% by weight of total composition; and wherein the weight ratio of dimethyloldimethylhydantoin to monomethyloldimethylhydantoin ranges from about 1:1.25 to about 3.5:1, are provided. These compositions may be prepared (1) by reacting dimethylhydantoin and a formaldehyde-containing source wherein the molar ratio of formaldehyde to dimethylhydantoin ranges from about 1.2:1 to about 1.55:1 or (2) by admixing (a) from about 80 to about 90% by weight of an aqueous solution of methyloldimethylhydantoin having greater than about 0.1% by weight of free formaldehyde with (b) about 20 to about 10% by weight of dimethylhydantoin based upon 100% weight of aqueous dimethyloldimethylhydantoin solution and dimethylhydantoin combined.

Abstract: The present invention relates to 2,4-dioxoimidazolidine compounds of the formula I ##STR1## a process for their preparation and their use as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.

Abstract: The subject of the present invention is the use of imexon for the production of pharmaceutical compositions with an immunosuppressive action. The present invention also provides pharmaceutical compositions containing imexon and further active materials.

Abstract: Compounds of formula(I) ##STR1## wherein R.sub.1 is nitro, halo, cyano and R.sub.2 is a group selected from ##STR2## wherein Y is oxygen or sulfur; X.sub.1 is NR wherein R is hydrogen, C.sub.1-8 alkyl or phenyl and pharmaceutically acceptable salts thereof are useful in the prevention or treatment of tissue damage induced by lipid peroxidation.

Abstract: N-Iodopropargyl hydantoin compounds, methods of preparing, compositions comprising, and methods of use as antimicrobials and antifungal agents in a variety of applications.

Abstract: Specific aspects of the cellular and humoral immune systems of a mammalian host are regulated by administering to the host a compound having a reactive immunoregulatory conformation whose precise three-dimensional structure is defined herein. Sorbinil, tolrestat, W-3681, and the other immunoregulatory agents described herein possess this reactive conformation and so are therapeutically useful for inhibiting delayed-type hypersensitivity, T-cell proliferation, and B-cell antibody production, without altering the normal cellularity of the immune system or the normal metabolites of the arachidonic acid pathway.

Abstract: Compounds of formula (I): ##STR1## wherein Q.sup.1 represents a phenyl group substituted by one or more halo; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl;R.sup.1 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl;R.sup.2 is phenyl(C.sub.1-4 alkyl) optionally substituted in the phenyl ring by one or more groups selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, SR.sup.b, SOR.sup.b, SO.sub.2 R.sup.b, OR.sup.b, NR.sup.b R.sup.c, NR.sup.b COR.sup.c, NR.sup.b COOR.sup.c, COOR.sup.b or CONR.sup.b R.sup.c, where R.sup.b and R.sup.c independently represent H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; andZ is O, S, NR.sup.8 or CR.sup.9 R.sup.10, where R.sup.8 represents H C.sub.1-6 alkyl, phenyl, phenyl(C.sub.1-4 alkyl), COR.sup.11, COOR.sup.11, CONR.sup.9 R.sup.10 where R.sup.11 is phenyl, phenyl(C.sub.1-4 alkyl) or C.sub.1-6 alkyl, and R.sup.9 and R.sup.10 are each H, C.sub.1-6 alkyl, phenyl or phenyl(C.sub.

Abstract: A method of treating or preventing motion sickness is disclosed which comprises administering an anti-motion sickness effective amount of an anticonvulsant compound such as phenytoin, ethotoin, primidone, ethosuximide or carbamazepine, in combination with a potentiating amount of an antitussive or cough suppressant agent such as dextromethorphan, levopropoxyphene, muscaphene, pholocodeine, or carbetapentene. The antitussive compounds of the present invention act as potentiating agents so as to enable effective treatment or prevention of motion sickness using a reduced amount of the anticonvulsant compound normally used in such treatment. The method of the present invention reduces the potential for various side effects and thus provides a safer and more effective method of treatment for motion sickness than prior art methods.

Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein R, R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl;R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-6 alkyl (including cycloalkyl) and aryl (wherein the alkyl or aryl group, which latter includes benzyl, is optionally substituted by one or more atoms or groups independently selected from halogen, C.sub.1-4 alkyl and aryl), provided R.sup.3 benzyl or substituted benzyl when R.sup.4 =H;m is an integer of from 0 to 2;n is an integer of from 0 to 3;(W) is a group of formula (i), (ii), (iii), or (iv) ##STR2## wherein Y is selected from oxygen, methylene and >N--R.sup.5, where R.sup.5 is hydrogen, C.sub.1-4 alkyl, or benzyl, Z and Z' are independently selected from >C.dbd.O, >C.dbd.

Abstract: The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives and pharmaceutical compositions containing at least one of hydantoin derivatives as hypoglycemic as well as hypolipidemic agents.The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton. The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.The compounds of the present invention represent a satisfactory hypoglycemic as well as hypolipidemic activity.

Abstract: The insecticidal composition of the present invention contains (a) 2,4-dioxo-1-(2-propynyl)-imidazolidin-3-ylmethyl chrysanthemate and (b) at least one carboxylic acid ester selected from the group consisting of monocarboxylic acid ester having 16 to 19 carbon atoms and dicarboxylic acid ester having 16 to 19 carbon atoms, the weight ratio of (a) to (b) being from 3:1 to 1:100.

Abstract: Novel compounds are disclosed having the formula ##STR1## and wherein R.sub.1, R.sub.2 and R.sub.3 are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.

Abstract: The invention relates to a hydantoin derivative, salt thereof, process for the preparation thereof, and medicine containing the derivative. The derivative is represented by the formula ##STR1## wherein M is --CONH--NHR.sup.1 group, --CONH--OR.sup.2 group, ##STR2## in which R.sup.1 is hydrogen atom, an alkyl group, an alkenyl group, a phenyl radical, a substituted phenyl group, a naphthyl radical, a substituted naphthyl group, a pyridyl radical, a furyl radical or a thienyl radical, R.sup.2 is a hydrogen atom, an alkyl group, a phenyl radical or a substituted phenyl group, R.sup.3 and R.sup.4 are the same or different independently, each being a phenyl radical, or an aralkyl group, or R.sup.3 may form a substituted or non-substituted C.sub.5-6 saturated heterocyclic ring together with R.sup.4 and a possible nitrogen or oxygen atom, R.sup.5 forms a substituted or non-substituted saturated heterocyclic ring together with R.sup.6 and a possible nitrogen or oxygen atom, R.sup.

Abstract: A therapeutic preparation for ulcers contains as a primary ingredient a compound having an aldose reductase inhibitory activity and can accelerate dermal metabolism. That compound may be d-6-fluoro-2,3-dihydro-2',5'-dioxo-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2-carboxyamide, d-2-chloromethyl-6-fluoro-2,3-dihydro-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione and d-2-bromomethyl-6-fluoro-2,3-dihydro-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione.

Abstract: Heterocyclic acetylenic amine compounds having the following structural formula ##STR1## having cholinergic agonist or antagonist activity useful in the treatment of mental disorders, extrapyramidal motor disorders, disorders of the parasympathetic nervous system and glaucoma or as analgesics for the treatment of pain. Typical central nervous system disorders for which the subject compounds can be used include cognitive disorders of all ages, including senile dementia, Alzheimer's disease and other related disorders. The compounds are particularly developed to improve mental performance when a mental deficiency is diagnosed.

Abstract: A series of ethers and thioethers of 5-methanol thiohydantoins, unsubstituted at the number one position heterocyclic nitrogen atom of the thiohydantoin ring, useful in reversing the effects of collagen and ADP-induced platelet aggregation.

Abstract: A method for controlling plant diseases and unwanted microorganisms by incorporating N-halohydantoins in nutrient-watering solutions. In the method, a treatment mixture is prepared comprising plant nutrients, N-halohydantoin and water. A plant is contacted with the treatment mixture to inhibit disease or the growth of unwanted microorganisms on, in or around the plant, with the mixture also being viable for use in stimulating healthy plant growth.

Abstract: A method of treating hormone-dependent cancer of an organ selected from the group consisting of bladder, brain, breast, lymphatic systems, kidney, liver, skin and ovaries in warm-blooded animals having such a cancer comprising administering to said warm-blooded animals an amount of 1-(3-'trifluoromethyl-4'-nitro-phenyl)-4,4-dimethyl-imidazoline-2,5-dione sufficient to combat said hormone-dependent cancer.

Abstract: A furan derivative and a pharmaceutically acceptable salt thereof having gastrointestinal enterokinetic activity which is expected to be used in a broad spectrum of diseases associated with gastrointestinal dyskinesia.

Abstract: A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier, in which the fluoride source provides a molar ratio of fluoride ion to hydantoin in the composition of from about 0.1:1 to about 100:1. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.

Abstract: A bactericidal composition and method for inhibiting and controlling the growth of the capsulated, facultative bacterium, Klebsiella pneumoniae, are disclosed. The composition comprises an amount, effective for the intended purpose of n-tributyl tetradecyl phosphonium chloride (TPC) and bromochlorohydantoin. The method comprises administering between about 0.1 to about 200 parts of this combined treatment (based on one million parts of the desired aqueous system) to the particular water containing system for which treatment is desired.

Abstract: Synergistic antimicrobial and biocidal compositions comprising 2-n-octyl-4-isothizolin-3-one and one or more known biocides for more effective, and broader control of miccroorganisms in various industrial systems are disclosed.

Abstract: Furanone compounds and compositions having anticholinergic activity are described. The compounds have the formula: ##STR1## wherein: the dashed line indicates either the 4,5-unsaturated or the 4,5-dihydrofuranone ring;R.sub.1 and R.sub.2 may be the same or different and are hydrogen, thienyl, furanyl, or cycloalkyl (C.sub.3 -C.sub.6), benzyl, phenyl, substituted phenyl or substituted benzyl wherein the phenyl or benzyl group may be substituted with halogen, trifluoromethyl, lower alkyl, lower alkoxy or hydroxy;R.sub.3, R.sub.4 and R.sub.5 may be the same or different and are hydrogen, lower alkyl, lower alkyl substituted with a halogen, alkoxy, amino or carboxylic acid group, an alkyl or alkylene bridge between R.sub.4 and R.sub.5 or R.sub.3 and the ring N, trifluoromethyl, nitro, a cycloalkyl group containing 3 to 6 carbons, halogen, benzyl, phenyl, substituted phenyl or substituted benzyl, for which the substituents are the same as those set forth for R.sub.1 and R.sub.2 substituted benzyl or phenyl.R.sub.

Abstract: A method of preparing an antimicrobial preservative system in a substantially anhydrous liquid form is disclosed. The antimicrobial preservative system inhibits or retards microbial growth when an effective antimicrobial amount is subsequently added to a medium capable of supporting undesirable microbial growth. More particularly, the preservative system comprises a condensation product of a 5,5-disubstituted hydantoin and formaldehyde prepared in the presence of a substantially anhydrous, water-miscible, solvent and an alkalizing agent. Also disclosed is a cold-stable, substantially anhydrous liquid preservative system comprising 1,3-dimethylol-5,5-dimethylhydantoin alone or in combination with an effective antimicrobial amount of at least one paraben preservative prepared by an embodiment of the disclosed method.

Abstract: Hydantoin derivatives of the formula ##STR1## wherein Ra and Rb are same or different, each being hydrogen atom, alkanoyl, substituted or none-substituted aroyl, heteroaroyl, alkoxycarbonyl, substituted or none-substituted aralkoxycarbonyl, aryloxycarbonyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, substituted or none-substituted N-aralkylcarbamoyl, alkoxyalkyl, 1-(acyloxy)-alkyl, alkylmercapto, substituted or none-substituted arylmercapto, alkylsulfinyl, substituted or none-substituted arylsulfinyl, alkylsulfonyl or substituted or none-substituted arylsulfonyl, but both of Ra and Rb do not concurrently mean hydrogen atom,a process for the preparation of the derivatives, and use thereof as an agent for preventing and curing chronic complications due to diabetes.

Abstract: This invention is for the use of DMDM Hydantoin as a pharmaceutical compound for the treatment of malconditions of mammalian and human skin and membranes. In particular, DMDM Hydantoin may be used to treat dermatological conditions such as acne, burns, and lacerations. DMDM Hydantoin may also be used as an aqueous spray, mouthwash and may be used to treat eye and ear infections as well as to treat mastitis in cattle.

Abstract: The present invention provides compounds of the general formulae: ##STR1## wherein R.sub.1 and R.sub.2, which can be the same or different, are hydrogen atoms or C.sub.1 -C.sub.5 -alkyl radicals, C.sub.3 -C.sub.5 -alkenyl radicals or phenyl radicals or, together with the carbon atom to which they are attached, form a saturated or unsaturated C.sub.3 -C.sub.7 ring, R.sub.3 and R.sub.4, which can be the same or different, are hydrogen atoms, straight-chained or branched C.sub.1 -C.sub.10 -alkyl radicals, straight-chained or branched C.sub.3 -C.sub.7 -alkenyl radicals, C.sub.3 -C.sub.7 -cycloalkyl radicals, C.sub.3 -C.sub.7 -cycloalkenyl radicals, phenyl, arylalkyl or hetarylalkyl radicals, R.sub.5 is a hydrogen atom or a lower alkyl radical and X is an oxygen or sulphur atom or an imino group.The present invention also provides processes for the preparation of these compounds, as well as pharmaceutical compositions with immunosuppressive action containing them.

Abstract: Several analogues of hexamethylene bis[acetamide] were found to be effective differentiating agents. The most effective of these compounds was 3,3'-(1,6-hexandiyl)bis[5,5-dimethyl-2,4-imidazolinedione].

Abstract: A bactericidal composition and method for inhibiting and controlling the growth of the capsulated, facultative bacterium, Klebsiella pneumoniae, are disclosed. The composition comprises an amount, effective for the intended purpose, of 2-bromo-2-nitropropane-l, 3-diol and an oxidizing biocide selected from the group consisting of hypochlorite, chlorine, and chlorine dioxide. The method comprises administering between about 0.1 to about 200 parts of this combined treatment (based on one million parts of the desired aqueous system) to the particular water containing system for which treatment is desired.

Abstract: The glycocyamidine derivatives of the present invention are represented by the following formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, is hydrogen or a lower alkyl group, preferably a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl, and R represents hydrogen or an acetyl group.which are useful as test reagents for diagnosis of renal failure.

Abstract: The present invention is directed to a novel method for controlling the growth of microorganisms on, in or near plants. more particularly, in one embodiment, growth of microorganisms is controlled on a surface that is in such proximity to a higher order plant that contacting such surface with a stream of water may cause liquid water from the stream to be deflected and contact the higher order plant or the growth medium in which it is rooted. In this embodiment, an N-halohydantoin is incorporated in water to produce treated water havng an N-halohydantoin concentration sufficient to inhibit the growth of microorganisms in the water or on a substrate to which the treated water is applied. Then the surface is contacted with the treated water, thereby inhibiting the growth of microorganisms on the surface, without harming the higher order plant by contact with the N-halohydantoin contained in any of the treated water that may contact the plant or the growth medium in which said plant is rooted.

Abstract: A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.

Abstract: An anticonvulsant composition comprising as an active ingredient an amount effective for controlling seizures in mammals of a compound selected from the group consisting of dextromethorphan and other non-narcotic, non-addictive, low-toxicity compounds that bind to the same central nervous system sites as dextromethorphan. The composition may also contain an antiepileptic hydantoin, which is potentiated by said compound.

Abstract: Several analogues of hexamethylene bis[acetamide] were found to be effective differentiating agents. The most effective of these compounds was 3,3'-(1,6-hexandiyl)bis[5,5-dimethyl-2,4-imidazolinedione].

Abstract: Substituted hydantoin analogues of essential amino acids are used as nutritive supplements in animal feed compositions.

Abstract: A compound of the formula: ##STR1## wherein X is a halogen atom and Y is a C.sub.1 -C.sub.4 alkyl group, a C.sub.2 -C.sub.4 alkenyl group, a C.sub.1 -C.sub.3 alkoxy group, a C.sub.3 -C.sub.4 alkenyloxy group, a C.sub.3 -C.sub.4 alkynyloxy group, a C.sub.2 -C.sub.3 alkenyl group substituted with phenyl, a C.sub.3 -C.sub.4 alkenyloxy group substituted with halogen, a C.sub.1 -C.sub.3 alkoxy group substituted with one member selected from the group consisting of halogen, C.sub.1 -C.sub.3 alkoxy, C.sub.1 -C.sub.3 alkanoyl, cyano, hydroxycarbonyl, C.sub.1 -C.sub.3 alkylaminocarbonyl and phenyl, or a group of the formula: --CH.sub.2 O--R.sup.1, --CH.dbd.CH--R.sup.2, --CH.dbd.N--R.sup.3 or --CO--R.sup.4 in which R.sup.1 is a C.sub.1 -C.sub.3 alkyl group, a C.sub.3 -C.sub.4 alkenyl group or a C.sub.3 -C.sub.4 alkynyl group, R.sup.2 is a cyano group, a methoxycarbonyl group or an acetyl group, R.sup.3 is a dimethylamino group or a phenyl group and R.sup.4 is a C.sub.1 -C.sub.

Abstract: Pharmaceutical compounds of the formula ##STR1## wherein R is H or CH.sub.3, R.sub.1 is H or OCH.sub.3, R.sub.2 is a C.sub.1 -C.sub.4 hydrocarbon group and X is an organic group. Also disclosed is a process for the preparation of these compounds. The compounds have dopamine agonist or antagonist activity.

Abstract: Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, ##STR3## in which R.sub.2 and R.sub.

Abstract: A bactericidal composition and method for inhibiting and controlling the growth of the capsulated, facultative bacterium, Klebsiella pneumoniae, are disclosed. The composition comprises an amount, effective for the intended purpose, of 2-bromo-2-nitropropane-1, 3-diol (BNPD) and an oxidizing biocide. The method comprises administering between about 0.1 to about 200 parts of this combined treatment (based on one million parts of the desired aqueous system) to the particular water containing system for which treatment is desired.

Abstract: The invention relates to spirohydantoins of the formula I ##STR1## where R.sub.1 and R.sub.2 are defined hereinbelow. Also disclosed are methods of preparation, pharmaceutical compositions containing at least one of these compounds, and methods of using said compounds for treatment and prevention of complications of diabetes and galactosemia.

Abstract: The present invention provides indole derivatives of the general formula: ##STR1## wherein R.sub.1 is a hydrogen atom or an alkyl, alkenyl, cycloalkyl, cycloalkenyl, carboxyl, cyano, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or aryl radical, R.sub.2 is a hydrogen atom or an alkyl, trihalogenomethyl, hydroxyl, cycloalkyl, cyano, carboxyl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl radical; R.sub.2 is a heterocyclic five-membered ring containing 1 to 4 heteroatoms or a heterocyclic six-membered ring containing 1 to 5 heteroatoms, the heteroatoms of the five- and six-membered rings being the same or different and being nitrogen, oxygen or sulphur and one or more of the nitrogen atoms optionally carrying an oxygen atom, the said five- and six-membered rings optionally being substituted by one or more alkyl, alkoxy, alkylthio, oxo, hydroxyl, nitro, amino, halogen or cyano groups; or R.sub.

Abstract: A broad spectrum preservative composition which comprises (a) a formaldehyde donor and (b) a halopropynyl compound; formulations containing such compositions, particularly personal care and household products; and a method of inhibiting the growth of microorganisms which includes contacting said microorganisms with the preservative composition.

Abstract: Permeability characterized in that the carboxy group at 1-position of the prostaglandin is combined with a cell membrane permeable substance having hydroxy group or amino group through the intermediation of an ester bond to the hydroxy group or an amide bond to the amino group are novel and have improved cell membrane permeability.

Abstract: Compounds of the formula I: ##STR1## wherein R.sub.1 =H, CH.sub.3 ; m=0,1; R.sub.2 =R.sub.3 =H or R.sub.2, R.sub.3 =bond, R.sub.4 =C.sub.1 -C.sub.4 hydrocarbon, n=1 or 2 and their pharmaceutically acceptable salts are antihypertensive agents. Their preparation and pharmaceutical compositions containing them are also described.

Abstract: A concentrated aqueous solution of the sodium salt of methionine, which is practically free from inorganic salts, is produced from the medium resulting from the hydrolysis of 5-(.beta.-mercaptoethyl)hydantoin.

Abstract: Hydantoin derivatives and salts thereof, the process for the preparation thereof, and medicines containing the same, wherein the hydantoin derivatives are represented by the general formula: ##STR1## wherein the substituents are defined hereinbelow. The hydantoin derivatives and salts thereof have excellent effects for the treamtment of the complications of the diabetes mellitus.

Abstract: Novel esters in all stereoisomeric forms and mixtures of said isomers of the formula ##STR1## wherein one of X and Y is ##STR2## and the other is selected from the group consisting of --CH.sub.2 --, --CH.sub.2 --CH.sub.2 -- and --CH.sub.2 --CH.sub.2 --CH.sub.2 --, n is an integer from 2 to 3 and R.sub.1 is selected from the group consisting of alkyl of 1 to 3 carbon atoms and alkenyl and alkynyl of 2 to 3 carbon atoms having pesticidal activity.

Abstract: 1-Hydroxypyrazoles of the formula ##STR1## where R.sup.1, R.sup.2 and R.sup.3 independently of one another are each hydrogen or halogen, and microbicides containing these compounds.